Thiazolidinedione energy restriction-mimetic agents
AssigneeThe Ohio State University Research Foundation
InventorsChing-Shih Chen, Jih-Hwa Guh
Life of this patent
Estimating the term…
Abstract
A method of inhibiting glycolysis in a subject by administering a pharmaceutical composition including a thiazolidinedione derivative to the subject is described. The thiazolidinedione derivatives are effective energy restriction mimetic agents, and can therefore be used to treat or prevent cancer in a subject, treat metabolic disorder, or increase the longevity of a subject. Various thiazolidinedione derivatives are also suitable for activating adenosine phosphate-activated protein kinase or inhibiting IL-6 expression.
Claims30
A method of inhibiting glycolysis in a subject, comprising administering to the subject a pharmaceutical composition including a compound of formula I:
- wherein R1 is hydrogen or hydroxyl;
- wherein R2 and R3 are selected from hydrogen, hydroxyl, halo, amino, methyl, methoxy, ethyl, ethoxy, nitro, aminosulfonyl, trifluoromethylsulfonyl, and haloalkyl moieties;
- and
- wherein R4 is selected from alkyl, alkenyl, cycloalkyl, and aryl groups.
A method for inhibiting glycolysis in a subject, comprising administering to the subject a pharmaceutical composition including a compound of formula II:
- wherein R1 is selected from aryl, alkyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups;
- wherein R2 is selected from hydrogen, halo, and nitro moieties and alkyl, alkoxy, and haloalkyl groups;
- and
- wherein R3 is selected from hydrogen and halo moieties and alkyl, alkoxy, and haloalkyl groups.
A method of inhibiting glycolysis in a subject, comprising administering to the subject a pharmaceutical composition including a compound of formula III:
- wherein R1 is lower alkyl group and R2 is selected from halo, methyl, methoxy, ethyl moieties.
A method of inhibiting glycolysis in a subject, comprising administering to the subject a pharmaceutical composition including a compound of formula IV:
- wherein R1 is a hydrogen, methyl, or trifluormethyl moiety;
- R2 is a methoxy or nitro moiety, and R3 is an alkyl or cycloalkyl group.
A method of activating adenosine monophosphate-activated protein kinase by providing an effective amount of a thiazolidinedione derivative selected from the group consisting of a compound of formula III:
- wherein R1 is lower alkyl group and R2 is selected from halo, methyl, methoxy, ethyl moieties;
- a compound of formula I:
- wherein R1 is hydroxyl;
- wherein R2 is trifluoromethyl;
- wherein R3 is hydrogen;
- and wherein R4 is an alkyl or cycloalkyl groups;
- and
- a compound of formula IV:
- wherein R1 is a hydrogen, methyl, or trifluormethyl moiety;
- R2 is a methoxy or nitro moiety, and R3 is an alkyl or cycloalkyl group.
A method of inhibiting IL-6 expression in a subject, comprising administering to the subject a pharmaceutical composition including a thiazolidinedione derivative selected from the group consisting of a compound of formula III:
- wherein R1 is a lower alkyl group and R2 is selected from halo, methyl, methoxy, ethyl moieties;
- a compound of formula I:
- wherein R1 is hydroxyl;
- wherein R2 is trifluoromethyl;
- wherein R3 is hydrogen;
- and wherein R4 is an alkyl or cycloalkyl groups;
- and
- a compound of formula IV:
- wherein R1 is a hydrogen, methyl, or trifluormethyl moiety;
- R2 is a methoxy or nitro moiety, and R3 is an alkyl or cycloalkyl group.
Dependencies are inferred from the claim text.